Consistently, patients with high levels of ADO were usually accompanied by an overexpression of CCL20 and its only known receptor CCR627,28, whereas low ADO expression was associated with low levels of CCL20 and CCR6 in gliomas (Fig. 5b; Supplementary Fig. S7; Supplementary Table 3). The gene discussed is CCR6; the disease is central nervous system cancer.